Time point | |||||
---|---|---|---|---|---|
Week 5 | Week 12 | Week 24 | Week 36 | Week 48 | |
SRM | |||||
ESSDAI rituximab | −1.11 | −0.97 | −1.04 | −0.44 | −0.20 |
ESSDAI placebo | −0.60 | −0.39 | 0.07 | 0.15 | −0.18 |
ES | |||||
ESSDAI rituximab | −1.09 | −1.04 | −1.15 | −0.50 | −0.26 |
ESSDAI placebo | −0.60 | −0.37 | 0.06 | 0.10 | −0.18 |
SRM and ES <0.5 were interpreted as small, 0.5–0.8 as moderate and >0.8 as large.
ES, effect size; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; EULAR, European League Against Rheumatism; pSS, primary Sjögren's syndrome; SRM, standardised response mean.